



JAPAN TOBACCO INC.
2-1, Toranomon 2-chome, Minato-ku
Tokyo 105-8422 JAPAN
Phone:03-3582-3111

FOR IMMEDIATE RELEASE

Tokyo, November 19, 2013

**Elvitegravir (JTK-303) received EU regulatory approval, JT's partner
Gilead Sciences announced**

A novel HIV integrase inhibitor, JT's original compound elvitegravir (JTK-303), has been approved by the European Medicines Agency (EMA). The drug is to be marketed as Vitekta™ in the European Union. Japan Tobacco Inc. (JT) (TSE:2914) announced that a statement has been issued to this effect by Gilead Sciences, Inc. (Gilead) of Foster City, California.

Elvitegravir interferes with HIV replication by blocking the ability of the virus to integrate into the genetic material of human cells. The Company licensed elvitegravir to Gilead in March 2005 with exclusive rights to develop and commercialize the drug worldwide, excluding Japan.

Prior to the approval of elvitegravir as a standalone agent, a once-daily single tablet regimen which contains four compounds: elvitegravir 150mg; cobicistat 150mg; emtricitabine 200mg; and tenofovir disoproxil fumarate 300mg, was provided to HIV patients in the United States, the European Union, Japan and other countries. Torii Pharmaceuticals Co., Ltd., JT's pharmaceutical subsidiary, has marketed this drug as Stribild® Combination Tablets in Japan, while Gilead has marketed this drug as Stribild® outside Japan.

* Elvitegravir and cobicistat as standalone agents are investigational products and their safety and efficacy have not yet been established in Japan.

* Vitekta and Stribild are trademarks or registered trademarks of Gilead Sciences, Inc.

###

Japan Tobacco Inc. is a leading international tobacco product company. Its products are sold in over 120 countries and its internationally recognized cigarette brands include Winston, Camel, Mevius/Mild Seven and Benson & Hedges. With diversified operations, JT is also actively present in pharmaceuticals, beverages and processed foods. The company's revenue was ¥2.120 trillion (US\$22,543 million()) in the fiscal year ended March 31, 2013.*

**Translated at the rate of ¥94.05 per \$1, as of March 29, 2013*

Contacts: Ryohei Sugata, General Manager
Media and Investor Relations Division
Japan Tobacco Inc. Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com